nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Allergic cutaneous angiitis—Methotrexate—ankylosing spondylitis	0.0387	0.0387	CcSEcCtD
Oritavancin—Abscess—Prednisolone—ankylosing spondylitis	0.0256	0.0256	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Methotrexate—ankylosing spondylitis	0.0251	0.0251	CcSEcCtD
Oritavancin—Abscess—Triamcinolone—ankylosing spondylitis	0.0236	0.0236	CcSEcCtD
Oritavancin—Abscess—Methylprednisolone—ankylosing spondylitis	0.0235	0.0235	CcSEcCtD
Oritavancin—Abscess—Dexamethasone—ankylosing spondylitis	0.0214	0.0214	CcSEcCtD
Oritavancin—Abscess—Betamethasone—ankylosing spondylitis	0.0214	0.0214	CcSEcCtD
Oritavancin—Extravasation—Betamethasone—ankylosing spondylitis	0.0194	0.0194	CcSEcCtD
Oritavancin—Extravasation—Dexamethasone—ankylosing spondylitis	0.0194	0.0194	CcSEcCtD
Oritavancin—Abscess—Prednisone—ankylosing spondylitis	0.0186	0.0186	CcSEcCtD
Oritavancin—Wheezing—Triamcinolone—ankylosing spondylitis	0.0181	0.0181	CcSEcCtD
Oritavancin—Abscess—Methotrexate—ankylosing spondylitis	0.0156	0.0156	CcSEcCtD
Oritavancin—Extravasation—Methotrexate—ankylosing spondylitis	0.0141	0.0141	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—ankylosing spondylitis	0.0133	0.0133	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—ankylosing spondylitis	0.0125	0.0125	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.0119	0.0119	CcSEcCtD
Oritavancin—Bronchospasm—Methylprednisolone—ankylosing spondylitis	0.0115	0.0115	CcSEcCtD
Oritavancin—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.0104	0.0104	CcSEcCtD
Oritavancin—Infestation—Methylprednisolone—ankylosing spondylitis	0.0104	0.0104	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.00943	0.00943	CcSEcCtD
Oritavancin—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.00918	0.00918	CcSEcCtD
Oritavancin—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.00867	0.00867	CcSEcCtD
Oritavancin—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.00844	0.00844	CcSEcCtD
Oritavancin—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00842	0.00842	CcSEcCtD
Oritavancin—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.00813	0.00813	CcSEcCtD
Oritavancin—Angioedema—Prednisolone—ankylosing spondylitis	0.0081	0.0081	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—ankylosing spondylitis	0.00765	0.00765	CcSEcCtD
Oritavancin—Angioedema—Triamcinolone—ankylosing spondylitis	0.00745	0.00745	CcSEcCtD
Oritavancin—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00743	0.00743	CcSEcCtD
Oritavancin—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00727	0.00727	CcSEcCtD
Oritavancin—Tachycardia—Prednisolone—ankylosing spondylitis	0.00706	0.00706	CcSEcCtD
Oritavancin—Myalgia—Triamcinolone—ankylosing spondylitis	0.00694	0.00694	CcSEcCtD
Oritavancin—Myalgia—Methylprednisolone—ankylosing spondylitis	0.00693	0.00693	CcSEcCtD
Oritavancin—Infestation—Methotrexate—ankylosing spondylitis	0.00689	0.00689	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00689	0.00689	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00688	0.00688	CcSEcCtD
Oritavancin—Angioedema—Betamethasone—ankylosing spondylitis	0.00676	0.00676	CcSEcCtD
Oritavancin—Angioedema—Dexamethasone—ankylosing spondylitis	0.00676	0.00676	CcSEcCtD
Oritavancin—Immune system disorder—Prednisone—ankylosing spondylitis	0.00668	0.00668	CcSEcCtD
Oritavancin—Infection—Triamcinolone—ankylosing spondylitis	0.00661	0.00661	CcSEcCtD
Oritavancin—Infection—Methylprednisolone—ankylosing spondylitis	0.0066	0.0066	CcSEcCtD
Oritavancin—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00651	0.00651	CcSEcCtD
Oritavancin—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00649	0.00649	CcSEcCtD
Oritavancin—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00648	0.00648	CcSEcCtD
Oritavancin—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00645	0.00645	CcSEcCtD
Oritavancin—Malnutrition—Prednisone—ankylosing spondylitis	0.00644	0.00644	CcSEcCtD
Oritavancin—Myalgia—Dexamethasone—ankylosing spondylitis	0.0063	0.0063	CcSEcCtD
Oritavancin—Myalgia—Betamethasone—ankylosing spondylitis	0.0063	0.0063	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00606	0.00606	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00605	0.00605	CcSEcCtD
Oritavancin—Infection—Betamethasone—ankylosing spondylitis	0.006	0.006	CcSEcCtD
Oritavancin—Infection—Dexamethasone—ankylosing spondylitis	0.006	0.006	CcSEcCtD
Oritavancin—Anaemia—Prednisone—ankylosing spondylitis	0.00595	0.00595	CcSEcCtD
Oritavancin—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00592	0.00592	CcSEcCtD
Oritavancin—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00592	0.00592	CcSEcCtD
Oritavancin—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00589	0.00589	CcSEcCtD
Oritavancin—Tachycardia—Betamethasone—ankylosing spondylitis	0.00589	0.00589	CcSEcCtD
Oritavancin—Angioedema—Prednisone—ankylosing spondylitis	0.00589	0.00589	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.00585	0.00585	CcSEcCtD
Oritavancin—Urticaria—Prednisolone—ankylosing spondylitis	0.00575	0.00575	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00574	0.00574	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—ankylosing spondylitis	0.00559	0.00559	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00557	0.00557	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.0055	0.0055	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.0055	0.0055	CcSEcCtD
Oritavancin—Myalgia—Prednisone—ankylosing spondylitis	0.00548	0.00548	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00545	0.00545	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—ankylosing spondylitis	0.00538	0.00538	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00533	0.00533	CcSEcCtD
Oritavancin—Urticaria—Triamcinolone—ankylosing spondylitis	0.00529	0.00529	CcSEcCtD
Oritavancin—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00527	0.00527	CcSEcCtD
Oritavancin—Infection—Prednisone—ankylosing spondylitis	0.00522	0.00522	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00521	0.00521	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00521	0.00521	CcSEcCtD
Oritavancin—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00516	0.00516	CcSEcCtD
Oritavancin—Tachycardia—Prednisone—ankylosing spondylitis	0.00513	0.00513	CcSEcCtD
Oritavancin—Skin disorder—Prednisone—ankylosing spondylitis	0.00511	0.00511	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—ankylosing spondylitis	0.00498	0.00498	CcSEcCtD
Oritavancin—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.0049	0.0049	CcSEcCtD
Oritavancin—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00489	0.00489	CcSEcCtD
Oritavancin—Urticaria—Betamethasone—ankylosing spondylitis	0.0048	0.0048	CcSEcCtD
Oritavancin—Urticaria—Dexamethasone—ankylosing spondylitis	0.0048	0.0048	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00479	0.00479	CcSEcCtD
Oritavancin—Dizziness—Prednisolone—ankylosing spondylitis	0.00478	0.00478	CcSEcCtD
Oritavancin—Pruritus—Triamcinolone—ankylosing spondylitis	0.00471	0.00471	CcSEcCtD
Oritavancin—Pruritus—Methylprednisolone—ankylosing spondylitis	0.0047	0.0047	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—ankylosing spondylitis	0.00458	0.00458	CcSEcCtD
Oritavancin—Rash—Prednisolone—ankylosing spondylitis	0.00456	0.00456	CcSEcCtD
Oritavancin—Dermatitis—Prednisolone—ankylosing spondylitis	0.00456	0.00456	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00455	0.00455	CcSEcCtD
Oritavancin—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00454	0.00454	CcSEcCtD
Oritavancin—Headache—Prednisolone—ankylosing spondylitis	0.00453	0.00453	CcSEcCtD
Oritavancin—Dizziness—Triamcinolone—ankylosing spondylitis	0.0044	0.0044	CcSEcCtD
Oritavancin—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00439	0.00439	CcSEcCtD
Oritavancin—Infection—Methotrexate—ankylosing spondylitis	0.00437	0.00437	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00431	0.00431	CcSEcCtD
Oritavancin—Nausea—Prednisolone—ankylosing spondylitis	0.0043	0.0043	CcSEcCtD
Oritavancin—Pruritus—Dexamethasone—ankylosing spondylitis	0.00427	0.00427	CcSEcCtD
Oritavancin—Pruritus—Betamethasone—ankylosing spondylitis	0.00427	0.00427	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—ankylosing spondylitis	0.00427	0.00427	CcSEcCtD
Oritavancin—Vomiting—Triamcinolone—ankylosing spondylitis	0.00423	0.00423	CcSEcCtD
Oritavancin—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00422	0.00422	CcSEcCtD
Oritavancin—Rash—Triamcinolone—ankylosing spondylitis	0.0042	0.0042	CcSEcCtD
Oritavancin—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00419	0.00419	CcSEcCtD
Oritavancin—Rash—Methylprednisolone—ankylosing spondylitis	0.00419	0.00419	CcSEcCtD
Oritavancin—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00418	0.00418	CcSEcCtD
Oritavancin—Urticaria—Prednisone—ankylosing spondylitis	0.00418	0.00418	CcSEcCtD
Oritavancin—Headache—Triamcinolone—ankylosing spondylitis	0.00417	0.00417	CcSEcCtD
Oritavancin—Headache—Methylprednisolone—ankylosing spondylitis	0.00416	0.00416	CcSEcCtD
Oritavancin—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00413	0.00413	CcSEcCtD
Oritavancin—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00413	0.00413	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.004	0.004	CcSEcCtD
Oritavancin—Dizziness—Betamethasone—ankylosing spondylitis	0.00399	0.00399	CcSEcCtD
Oritavancin—Dizziness—Dexamethasone—ankylosing spondylitis	0.00399	0.00399	CcSEcCtD
Oritavancin—Nausea—Triamcinolone—ankylosing spondylitis	0.00395	0.00395	CcSEcCtD
Oritavancin—Nausea—Methylprednisolone—ankylosing spondylitis	0.00394	0.00394	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00387	0.00387	CcSEcCtD
Oritavancin—Vomiting—Dexamethasone—ankylosing spondylitis	0.00384	0.00384	CcSEcCtD
Oritavancin—Vomiting—Betamethasone—ankylosing spondylitis	0.00384	0.00384	CcSEcCtD
Oritavancin—Rash—Dexamethasone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Oritavancin—Rash—Betamethasone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Oritavancin—Dermatitis—Betamethasone—ankylosing spondylitis	0.0038	0.0038	CcSEcCtD
Oritavancin—Dermatitis—Dexamethasone—ankylosing spondylitis	0.0038	0.0038	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00379	0.00379	CcSEcCtD
Oritavancin—Headache—Betamethasone—ankylosing spondylitis	0.00378	0.00378	CcSEcCtD
Oritavancin—Headache—Dexamethasone—ankylosing spondylitis	0.00378	0.00378	CcSEcCtD
Oritavancin—Pruritus—Prednisone—ankylosing spondylitis	0.00372	0.00372	CcSEcCtD
Oritavancin—Diarrhoea—Prednisone—ankylosing spondylitis	0.0036	0.0036	CcSEcCtD
Oritavancin—Nausea—Dexamethasone—ankylosing spondylitis	0.00359	0.00359	CcSEcCtD
Oritavancin—Nausea—Betamethasone—ankylosing spondylitis	0.00359	0.00359	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—ankylosing spondylitis	0.00349	0.00349	CcSEcCtD
Oritavancin—Dizziness—Prednisone—ankylosing spondylitis	0.00348	0.00348	CcSEcCtD
Oritavancin—Vomiting—Prednisone—ankylosing spondylitis	0.00334	0.00334	CcSEcCtD
Oritavancin—Rash—Prednisone—ankylosing spondylitis	0.00332	0.00332	CcSEcCtD
Oritavancin—Dermatitis—Prednisone—ankylosing spondylitis	0.00331	0.00331	CcSEcCtD
Oritavancin—Headache—Prednisone—ankylosing spondylitis	0.00329	0.00329	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00324	0.00324	CcSEcCtD
Oritavancin—Nausea—Prednisone—ankylosing spondylitis	0.00312	0.00312	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—ankylosing spondylitis	0.00279	0.00279	CcSEcCtD
Oritavancin—Rash—Methotrexate—ankylosing spondylitis	0.00277	0.00277	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—ankylosing spondylitis	0.00277	0.00277	CcSEcCtD
Oritavancin—Headache—Methotrexate—ankylosing spondylitis	0.00275	0.00275	CcSEcCtD
Oritavancin—Nausea—Methotrexate—ankylosing spondylitis	0.00261	0.00261	CcSEcCtD
